Total labs
30
Total footprint
30,000 sq ft
OMX offers the much-needed lab space in Bristol that scaling Deep Tech companies often struggle to find — and it will do so within the supportive, well-connected ecosystem built by Science Creates.
Join our community of scientific entrepreneurs developing technologies that include groundbreaking cancer treatments, enhanced battery technologies and seaweed-based biomaterials.
Located in the heart of Bristol and connected to our Old Market incubator, OMX is designed with the specialised services and features that Deep Tech R&D demands, plus the flexibility that growing ventures need.
With 30,000 sq ft of lab, office and meeting space, OMX offers a range of options depending on the size of your company — from lab-only options to renting full suites including two labs and a private office.
Membership includes access to our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.





Discover the lab space that's available to rent in our newest Bristol incubator and discuss your scaling startup needs with our team today.



Travel between locations is measured in walking distance
St Philips Rd & Midland Rd
0.5 miles / 11 min
0.7 miles / 15 min

Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.

Dimension Biotechnologies is addressing unmet global vascular health challenges by improving diagnostic tools. Its transformative technology non-invasively monitors microscopic blood vessels at the biochemical level enabling doctors, drug developers and scientists to rapidly assess microvascular health and disease.

GenomeKey is transforming how healthcare clinicians diagnose and treat infections like sepsis to improve patient outcomes. Using cutting-edge machine learning and DNA sequencing, the company is developing a next-generation diagnostic device to identify bacterial genomes and determine their antimicrobial susceptibility directly from patient blood in just a few hours, rather than days. This enables clinicians to prescribe the right antibiotics for patients with much more efficiency and accuracy, reducing costs, minimising unnecessary antibiotic use and ultimately saving millions of lives from the world’s leading cause of death.




Fine Agrochemicals is enhancing crop quality for fruit and flower growers in agricultural, ornamental and landscape markets using its plant growth regulator (PGR) technology. Its PGR products, made using naturally occurring molecules through fermentation and combined with chemically synthesised compounds, help stimulate plant cells to enhance nutrient levels and targeted growth for improved crop outputs.

NuNano is advancing the field of atomic force microscopy with high-precision probes for nanometer-scale imaging. Its proprietary microfabrication processes produce reliable, high-quality probes with market-leading dimensional tolerances. It also provides dedicated support to its customers, from probe selection to storage, for a seamless user experience.

Dimension Biotechnologies is addressing unmet global vascular health challenges by improving diagnostic tools. Its transformative technology non-invasively monitors microscopic blood vessels at the biochemical level enabling doctors, drug developers and scientists to rapidly assess microvascular health and disease.




Epinal is revolutionising the detection and prevention of narcotic-impaired behaviour for safer roads, flights and workplaces. Utilising AI and novel biotechnology that mimics natural sensory mechanisms, it’s developing a handheld breathalyser that generates rapid results with extreme sensitivity and selectivity.

Scarlet Therapeutics is developing a proprietary platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Its technologies are underpinned by learnings from decades of research including the groundbreaking RESTORE clinical study run by NHS Blood and Transplant and the University of Bristol, investigating transfusion of lab-grown blood into patients. By generating tRBCs with high levels of therapeutic proteins from cell lines rather than from donated stem cells, Scarlet Therapeutics aims to address significant efficacy and manufacturing issues faced in the field.

Transdermal Diagnostics is pioneering the development of bio-wearables that enhance the prevention, diagnosis and management of chronic conditions like diabetes. Its unique sensing technology aims to create the world’s first needle-free continuous monitor for glucose and other health biomarkers. By analysing hair follicles, the adhesive skin patch and transmitter wirelessly communicate information straight to a smartphone app, facilitating a transformative shift in patient care and quality of life for those with diabetes.


